Latest news

Daily Snap - 30. October 2025

Daily Snap - 30. October 2025

Joachim Eeckhout
Regeneron agrees to collaborate with ModeX for a $1B+ antibody R&D

Regeneron agrees to collaborate with ModeX for a $1B+ antibody R&D

Joachim Eeckhout
BridgeBio scores second major 2025 win with trial in rare endocrine disorder

BridgeBio scores second major 2025 win with trial in rare endocrine disorder

Joachim Eeckhout
Daily Snap - 29. October 2025

Daily Snap - 29. October 2025

Joachim Eeckhout
GSK commits $745M on precision COPD drug targeting overlooked patients

GSK commits $745M on precision COPD drug targeting overlooked patients

Joachim Eeckhout
Zag Bio launches with $80M to reprogram the immune system against autoimmune diseases

Zag Bio launches with $80M to reprogram the immune system against autoimmune diseases

Joachim Eeckhout
Daily Snap - 28. October 2025

Daily Snap - 28. October 2025

Joachim Eeckhout
Hemab raises $157M to lead next wave in rare blood disorder treatments

Hemab raises $157M to lead next wave in rare blood disorder treatments

Joachim Eeckhout
Novartis buys Avidity for $12B to lead RNA drug push for muscle disease

Novartis buys Avidity for $12B to lead RNA drug push for muscle disease

Joachim Eeckhout
Daily Snap - 27. October 2025

Daily Snap - 27. October 2025

Joachim Eeckhout
Lilly acquires struggling Adverum in backloaded gene therapy deal

Lilly acquires struggling Adverum in backloaded gene therapy deal

Joachim Eeckhout
Biogen bets big on immune drug from Vanqua Bio in $1B+ deal

Biogen bets big on immune drug from Vanqua Bio in $1B+ deal

Joachim Eeckhout
FirstBack
345678910
Next Last